A previous study exploring the biological mechanisms associated with paclitaxel resistance in ovarian cancer suggested that FOXO1 expression may represent a negative predictor of response to treatment, although this observation was based on a relatively small cohort of patients and the results were only marginally significant ( Goto et al , 2008 ).
← all excerpts
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
1
—
—